Using tissue microarrays containing pairs of samples from tumors and normal peripheral tissue, Spry1 was shown to be decreased in 39% of prostate cancer compared with matched normal prostate tissue (Kwabi-Addo et al. 2004). This evidence concerns the gene SPRY1 and prostate carcinoma.